Basel, April 2017 – MTIP MedTech Innovation Partners AG has closed its first fund significantly above expectation at CHF 60 million.
After its launch a year ago, MTIP’s first fund closed at a total of just under CHF 60 million. Due to strong investor demand this is considerably higher than the CHF 40 million targeted at the outset. “A first fund of this magnitude is exceptional in the industry and a great success for our investors and us,” explains Dr. Christoph Kausch, CEO of MTIP. The capital comes from institutional investors such as pension funds and family offices, hospitals, foundations and qualified private individuals. MTIP will use this fund to invest in a portfolio of around 10 startups in the medical technology sector. The aim is to support these businesses and to facilitate their further development into successful companies. Having invested in two startups (Coramaze and Reactive Robotics) already, additional investments are expected later this year as MTIP’s project pipeline is looking promising with additional attractive opportunities. “MTIP’s involvement in the innovation landscape, from university research to practical use in hospitals and an understanding of the relevant MedTech players’ portfolio strategies are important success factors in our business model”, emphasises board president Dr. Felix Grisard. In the selection process of companies MTIP places a clear focus on health economic benefits and patient-relevant innovations. MTIP builds sustainable investments that facilitate improved health care at home and abroad and combine economic success with added value for the community.
Share the Article
Dealroom Report: Tooling the Physicians of the Future
European startups addressing clinical capacity bottlenecks
MTIP Office Featured in Swiss Office Blog
MTIP Office Featured in Swiss Office Blog
Diversity, Equity, and Inclusion: The 3 Key Drivers for Success
We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.
Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch
Growth Capital Decisions
Rahel Hafner Receives Certificate in ESG Investing by CFA Institute
Rahel Hafner Receives Certificate in ESG Investing
What Makes a Great Founder/Investor Relationship?
Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva
MTIP’s HealthCare Clinic 2022
This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
